Randall B. Brenner Paratek Pharmaceuticals, Inc. (PRTK) insider trading activity

Randall B. Brenner is Chief Development & Regulatory of Paratek Pharmaceuticals, Inc.. Currently has a direct ownership of 0 shares of PRTK, which is worth approximately $0. The most recent transaction as insider was on Sep 21, 2023, when has been sold 415,209 shares (Common Stock) at a price of $0.0 per share, resulting in proceeds of $0. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 0

0% 3M change

0% 12M change

Total Value Held $0

Randall B. Brenner Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Sep 21 2023	SELL Sale (or disposition) back to the issuer	-	415,209 Reduced 100.0%	0 Common Stock
Aug 09 2023	SELL Open market or private sale	$60,726 $2.2 p/Share	27,603 Reduced 6.23%	415,209 Common Stock
Aug 08 2023	BUY Grant, award, or other acquisition	-	67,500 Added 13.23%	442,812 Common Stock
Dec 21 2022	SELL Open market or private sale	$9,032 $1.99 p/Share	4,539 Reduced 1.34%	335,312 Common Stock
Dec 20 2022	BUY Grant, award, or other acquisition	-	15,000 Added 4.23%	339,851 Common Stock
Dec 13 2022	SELL Open market or private sale	$35,626 $1.96 p/Share	18,177 Reduced 5.3%	324,851 Common Stock
Dec 12 2022	SELL Open market or private sale	$21,987 $1.98 p/Share	11,105 Reduced 3.14%	343,028 Common Stock
Oct 28 2022	SELL Open market or private sale	$12,200 $3.47 p/Share	3,516 Reduced 0.98%	354,133 Common Stock
Oct 25 2022	BUY Grant, award, or other acquisition	-	8,500 Added 2.32%	357,649 Common Stock
Aug 09 2022	SELL Open market or private sale	$52,157 $2.66 p/Share	19,608 Reduced 5.32%	349,149 Common Stock
Aug 08 2022	BUY Grant, award, or other acquisition	-	47,727 Added 11.46%	368,757 Common Stock
Mar 15 2022	BUY Grant, award, or other acquisition	-	67,500 Added 17.37%	321,030 Common Stock
Dec 15 2021	SELL Open market or private sale	$67,381 $4.27 p/Share	15,780 Reduced 5.86%	253,530 Common Stock
Dec 14 2021	SELL Open market or private sale	$33,365 $4.37 p/Share	7,635 Reduced 2.76%	269,310 Common Stock
Dec 13 2021	SELL Open market or private sale	$19,797 $4.42 p/Share	4,479 Reduced 1.59%	276,945 Common Stock
Aug 17 2021	SELL Open market or private sale	$44,882 $5.12 p/Share	8,766 Reduced 3.02%	281,424 Common Stock
Aug 16 2021	BUY Grant, award, or other acquisition	-	21,250 Added 6.82%	290,190 Common Stock
Jun 04 2021	SELL Open market or private sale	$96,787 $9.7 p/Share	9,978 Reduced 3.58%	268,940 Common Stock
May 27 2021	BUY Grant, award, or other acquisition	-	28,636 Added 9.31%	278,918 Common Stock
Mar 30 2021	BUY Grant, award, or other acquisition	-	121,500 Added 32.68%	250,282 Common Stock
Dec 14 2020	SELL Open market or private sale	$58,780 $6.71 p/Share	8,760 Reduced 6.37%	128,782 Common Stock
Dec 11 2020	SELL Open market or private sale	$42,840 $6.95 p/Share	6,164 Reduced 4.29%	137,542 Common Stock
Nov 13 2020	SELL Open market or private sale	$49,557 $5.93 p/Share	8,357 Reduced 5.5%	143,706 Common Stock
Nov 12 2020	BUY Grant, award, or other acquisition	-	21,250 Added 12.26%	152,063 Common Stock

RBB

Randall B. Brenner

Chief Development & Regulatory

Boston, MA

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells PRTK shares.

Notify only if

Value

Insider Trading

Get notified when an Paratek Pharmaceuticals, Inc. insider buys or sells PRTK shares.

Notify only if

Operation

Value

Type

News

Receive news related to Paratek Pharmaceuticals, Inc.

Track Activities on PRTK

Account